Search

Viramune®

For the combination therapy of HIV-1 infection and (in several countries) for the prevention of mother-to-child transmission of HIV-1 in pregnant women who are not taking antiretroviral therapy at time of labour. Prolonged release tablets for once-da

Twynsta®

Treatment of hypertension alone or with other antihypertensive agents. As initial therapy in patients likely to need multiple antihypertensive agents to achieve their blood pressure goals (USA). Add-on therapy in adult patients with not adequately co

preserved-heart-failure-treatment-approval-europe

Oncology

We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in oncology.

License to develop new fibro-inflammatory disease treatments

collaboration criving innovation

In conversation with Dr. Megan Grether, Global Head of Business Development & Licensing, Boehringer Ingelheim Animal Health.

Targeting Tumor Stroma

Boehringer Ingelheim’s research approach in stromal biology may lead to new medicines that will change the face of cancer and give new hope to patients

Giotrif®

For the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have activating epidermal growth factor receptor (EGFR) mutations. For the treatment of patients with locally advanced or metastatic NSCLC of squamous hist

Biopharmaceuticals: large molecules, enormous potential

Researching, developing and manufacturing biopharmaceuticals is a highly complex and lengthy process, but it has enormous potential.

Collaboration Boehringer Ingelheim Veeva technology

Boehringer Ingelheim selects Veeva Development Cloud worldwide to bring innovative therapies to patients faster

Immunology Respiratory Research

Find out more about our research and development in Immunology & Respiratory diseases

discontinuation-bi-1467335-diabetic-retinopathy

The discontinuation of the development of BI 1467335 in diabetic retinopathy has been announced

Clinical Studies

Boehringer Ingelheim partners with PetMedix

Partnering with PetMedix on Ky9™ platform cutting edge technology as a means to bring innovative new therapies to improve health of animals

VSV-GP

International Postdocs realize their potential in Biberach

Three talented postdocs report on what they are working at Boehringer Ingelheim's research site in Biberach and what attracts them to the company.

Agreement-to-acquire-NBE-Therapeutics

Boehringer Ingelheim to acquire NBE-Therapeutics to significantly enhance cancer pipeline portfolio with antibody-drug conjugates.

SIRPα antagonist

BI Focuses COVID-19 Clinical Research on Alteplase

BI focuses its COVID-19 therapy research on the development of alteplase as a potential treatment for COVID-19 patients with severe breathing problems

Trajenta®

Treatment of type 2 diabetes mellitus to improve glycaemic control in adults, used in monotherapy (if metformin is not tolerated or contraindicated) or in combination therapy.

Professor Gregory Lip introduces the GLORIA™-AF Registry

Our Venture Fund on the search for groundbreaking trends

The Boehringer Ingelheim Venture Fund acquires minority stakes in biotech start-ups, and even supports the majority before and during their founding.

Why cancer care is personal for us

At Boehringer Ingelheim, we have made a generational commitment to transforming cancer care, with the ultimate goal of curing a range of cancers.

Science Stories

Partnership for first-in-class cancer and CRM treatments

Boehringer Ingelheim partners with OSE Immunotherapeutics to develop first-in-class cancer and CRM treatments

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers